Pages that link to "Q43878216"
Jump to navigation
Jump to search
The following pages link to The effect of pravastatin on acute rejection after kidney transplantation--a pilot study (Q43878216):
Displaying 50 items.
- HMG CoA reductase inhibitors (statins) for kidney transplant recipients (Q24200984) (← links)
- HMG CoA reductase inhibitors (statins) for kidney transplant recipients (Q24241098) (← links)
- Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? (Q24804153) (← links)
- Tacrolimus/cerivastatin interaction study in liver transplant recipients (Q28345569) (← links)
- HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival (Q33548525) (← links)
- Immunosuppressive and antiproliferative effects of HMG-CoA reductase inhibitors (Q33636573) (← links)
- Choice of immunosuppressive drugs and individualization of immunosuppressive therapy for kidney transplant patients (Q33806753) (← links)
- Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience (Q33826469) (← links)
- Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation (Q33843614) (← links)
- Prenylation inhibitors in renal disease (Q33854965) (← links)
- Early statin use is an independent predictor of long-term graft survival (Q33871260) (← links)
- The effect of simvastatin on lowering panel reactive antibody titer in sensitized dialysis patients: a randomized placebo controlled clinical trial (Q33871644) (← links)
- Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation (Q34012822) (← links)
- Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after renal transplantation (Q34075414) (← links)
- Syndrome X following renal transplantation (Q34199971) (← links)
- Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation (Q34373712) (← links)
- Total cholesterol and risk of mortality in the oldest old (Q34443709) (← links)
- Can the potential benefits of statins in general medical practice be extrapolated to liver transplantation? (Q34468860) (← links)
- Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? (Q34478635) (← links)
- Metabolic complications after renal transplantation from a living donor: experience of the Ibn Sina university hospital of Rabat (Q34551775) (← links)
- Distribution of cyclosporin in organ transplant recipients (Q34749073) (← links)
- New concepts in organ preservation (Q34786123) (← links)
- HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection. (Q34967056) (← links)
- Cardiovascular toxicities of immunosuppressive agents (Q34976738) (← links)
- Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? (Q34981331) (← links)
- Worsening of hyperglycemia due to atorvastatin in a renal transplant patient (Q35573997) (← links)
- Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein(a), and lipid abnormalities in renal diseases and following solid organ transplantation (Q35588639) (← links)
- Statins in solid organ transplantation: is there an immunosuppressive effect? (Q35804356) (← links)
- Fluvastatin and fluvastatin extended release: a clinical and safety profile. (Q35879055) (← links)
- Do statins offer therapeutic potential in inflammatory arthritis? (Q35952218) (← links)
- Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis (Q36070412) (← links)
- HMG-CoA reductase inhibitors and the kidney (Q36255411) (← links)
- Anti-inflammatory effects of statins: clinical evidence and basic mechanisms (Q36337932) (← links)
- Are statins analogues of vitamin D? (Q36525289) (← links)
- Statin therapy in patients with chronic kidney disease: to use or not to use. (Q36558703) (← links)
- Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients? (Q36577189) (← links)
- Potential roles for statins in critically ill patients (Q36920701) (← links)
- Management of dyslipidemia in patients after solid organ transplantation (Q37158327) (← links)
- Does African American Race Impact Statin Efficacy in Renal Transplant Outcomes? (Q37226086) (← links)
- A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation (Q37246506) (← links)
- Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. (Q37247613) (← links)
- Pleiotropic vasoprotective effects of statins: the chicken or the egg? (Q37403235) (← links)
- Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis (Q37638675) (← links)
- Simvastatin therapy in lymphocyte cross-match-positive kidney transplantation candidates (Q40496909) (← links)
- Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease (Q41348490) (← links)
- Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients. (Q42837781) (← links)
- Extended experience with a steroid minimization immunosuppression protocol in pediatric renal transplant recipients (Q43256698) (← links)
- Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection (Q43628293) (← links)
- Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial (Q43701061) (← links)
- The effect of simvastatin on panel-reactive antibody and crossmatch positivity (Q43702817) (← links)